Treatment Preferences Among Patients with DLBCL

The diffuse large B-cell lymphoma (DLBCL) treatment landscape has evolved to include novel targeted therapies and chimeric antigen T-cell (CAR-T) therapy. Whereas the role of shared decision-making in cancer treatment and the effect of inpatient hospitalization on health-related quality of life in other diseases are understood, data on patient preferences regarding DLBCL treatment and inpatient hospitalization are lacking. This study aimed to examine DLBCL patient preferences of treatment characteristics, including the need for hospitalization.

Data were taken from the Adelphi DLBCL II Disease-Specific Programme, a point-in-time survey of patients with DLBCL in Western Europe (including Germany, France, Spain, and the United Kingdom) and the United States, between January and May of 2021. Patients voluntarily completed a self-completion form-based survey capturing rated acceptance for attributes of treatments on a 7-point Likert scale, with 1 representing total disagreement and 7 representing total agreement. Scores of 6 to 7 were interpreted as agreement, scores of 3 to 5 were indifferent, and scores of 1 to 2 were disagreement.

A total of 441 patients with DLBCL completed the survey. Mean age was 65 years, 64% were male, and 81% were on second or later lines of therapy. While 31% of patients deemed hospitalization for 1 to 2 weeks acceptable during the first 1 or 2 months of treatment if they were less likely to experience side effects (Western Europe: 33%; US: 25%), 50% of patients were indifferent (Western Europe: 52%; US: 41%). Seventeen percent of patients reported not wanting to be hospitalized for treatment even in the presence of a better side-effect profile. While 37% of patients deemed hospitalization at the time of treatment initiation to be acceptable in the presence of improved effectiveness (Western Europe: 38%; US: 29%), 43% of patients were indifferent (Western Europe: 44%; US: 38%). Twenty percent of patients reported not wanting to be hospitalized for treatment even in the presence of better effectiveness (Western Europe: 17%; US: 34%).

Between 80% and 90% of the patients surveyed were either in favor of or indifferent towards hospitalization for treatment in the presence of preferred safety or improved effectiveness, suggesting that safety and effectiveness are higher priority concerns than the need for hospitalization for most patients with DLBCL.


Johnson P, Quek R, Bailey A, et al. Treatment preferences among patients with diffuse large B-cell lymphoma: a survey across Western Europe and the United States. Presented at: 2022 Academy of Managed Care Pharmacy Nexus Annual Meeting; October 11-14, 2022; National Harbor, MD. Poster C49.

Related Items

Conference Correspondent Coverage is Brought to You by the Publishers of:
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications